Optimization of Luminescent Assay for Screening of Cyclin-Dependent Kinase 2 Inhibitors

被引:2
|
作者
Suthar, M. P. [1 ]
Patel, M. M. [2 ]
机构
[1] Ganpat Univ, Shree SK Patel Coll Pharmaceut Educ & Res, Dept Biotechnol, Kherva 382711, India
[2] Kalol Inst Pharm, Kalol 382721, India
关键词
Cyclin-dependent kinase 2; histone H1; luminescence; assay; optimization; PROTEIN-KINASES;
D O I
10.4103/0250-474X.70472
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cyclin-dependent kinases are most extensively studied targets for cancer chemotherapy since the tumor cells exhibit false checkpoints and can proliferate even if the genome is compromised. Cyclin-dependent kinases ensure the tight regulation of the cell cycle execution by mediating phosphorylation of cellular proteins. Deregulation of the cyclin-dependent kinase 2 activity by cellular and external factors leads to many diseases like cancers. Different methods like radiolabeled, fluorescence and luminescence are available for screening of library of compounds against kinases. However, bioluminescent methods offer several advantages like low background and no effect of fluorescent compound interference. Present study is focused on development, optimization and validation of cyclin-dependent kinase 2 assay which is suitable for identification potent and selective, ATP competitive and non-competitive inhibitors of cyclin-dependent kinase 2. The aim of present investigation was to optimize the assay for cyclin-dependent kinase 2/cylin A and cyclin-dependent kinase 2/cyclin E with use of bioluminescence based biochemical reaction. Both cyclin-dependent kinase 2 which are cyclin-dependent kinase 2/cyclin A and cyclin-dependent kinase 2/cyclin E complexes, have different affinity for ATP. Therefore, both isoform analogs of cyclin-dependent kinase 2 were optimized separately. Optimum cyclin-dependent kinase 2/cyclin A and cyclin-dependent kinase 2/cyclin E concentration were found to be 250 ng/well and 200 ng/well, respectively. Optimum substrate (histone H1) concentration was found to be 2.5 mg/ml for both cyclin-dependent kinase 2 analogs. Optimum reaction time was found to be 20 min for both cyclin-dependent kinase 2/cyclin complexes.
引用
收藏
页码:290 / 294
页数:5
相关论文
共 50 条
  • [31] Cyclin-dependent kinase inhibitors and angiogenesis in sinonasal carcinomas
    Bottini, Consuelo
    Rossi, Valentina
    Valente, Guido
    Tessitore, Luciana
    CANCER RESEARCH, 2006, 66 (08)
  • [32] Novel potent pharmacological cyclin-dependent kinase inhibitors
    Wesierska-Gadek, Jozefa
    Chamrad, Ivo
    Krystof, Vladimir
    FUTURE MEDICINAL CHEMISTRY, 2009, 1 (09) : 1561 - 1581
  • [33] Expression of cyclin-dependent kinase inhibitors in vascular disease
    Tanner, FC
    Yang, ZY
    Duckers, E
    Gordon, D
    Nabel, GJ
    Nabel, EG
    CIRCULATION RESEARCH, 1998, 82 (03) : 396 - 403
  • [34] Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
    Giannone, Gaia
    Tuninetti, Valentina
    Ghisoni, Eleonora
    Genta, Sofia
    Scotto, Giulia
    Mittica, Gloria
    Valabrega, Giorgio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (09)
  • [35] Cyclin-dependent kinase inhibitors move into Phase III
    Malini Guha
    Nature Reviews Drug Discovery, 2012, 11 : 892 - 894
  • [36] Cyclin-dependent kinase inhibitors closer to market launch?
    Galons, Herve
    Oumata, Nassima
    Gloulou, Olfa
    Meijer, Laurent
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (08) : 945 - 963
  • [37] Functional analysis of cyclin-dependent kinase inhibitors of Arabidopsis
    De Veylder, L
    Beeckman, T
    Beemster, GTS
    Krols, L
    Terras, P
    Landrieu, I
    Van der Schueren, E
    Maes, S
    Naudts, M
    Inzé, D
    PLANT CELL, 2001, 13 (07): : 1653 - 1667
  • [38] ROLE OF THE CYCLIN-DEPENDENT KINASE INHIBITORS IN THE DEVELOPMENT OF CANCER
    HIRAMA, T
    KOEFFLER, HP
    BLOOD, 1995, 86 (03) : 841 - 854
  • [39] Cyclin-dependent kinase inhibitors: novel anticancer agents
    Mani, S
    Wang, CG
    Wu, KM
    Francis, R
    Pestell, R
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (08) : 1849 - 1870
  • [40] Virtual Screening for Potential Allosteric Inhibitors of Cyclin-Dependent Kinase 2 from Traditional Chinese Medicine
    Lu, Fang
    Luo, Ganggang
    Qiao, Liansheng
    Jiang, Ludi
    Li, Gongyu
    Zhang, Yanling
    MOLECULES, 2016, 21 (09)